Jevtana, Zytiga and Xtandi to push prostate cancer market to new heights
This article was originally published in Scrip
Executive Summary
A recent influx of novel drugs to treat metastatic castration-resistant prostate cancer (mCRPC) will help drive strong growth in this market over the next ten years, a new forecast from Datamonitor has found.